Marker Therapeutics, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Juan Vera, serving as both CEO and Principal Financial Officer, signed standard Sarbanes-Oxley Section 302 and 906 certifications on August 14, 2026 for the Q2 2026 10-Q period ended June 30, 2026. The certifications attest that the financial statements fairly present the company's financial condition and that disclosure controls and internal controls over financial reporting are effective; no material weaknesses or fraud are disclosed.
Why this rating
Routine SOX compliance certification. No substantive business event disclosed. Sole officer holding both executive and financial roles is a governance note but standard for micro-cap.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.